Suppr超能文献

验证患者监护仪(版本 2.0):癌症患者系统评估工具的回顾。

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.

机构信息

Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

J Pain Symptom Manage. 2010 Oct;40(4):545-58. doi: 10.1016/j.jpainsymman.2010.01.017. Epub 2010 Jun 25.

Abstract

CONTEXT

The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has not been validated nor tested in the academic setting.

OBJECTIVES

To validate and test the PCM 2.0 in three cancer populations.

METHODS

Two hundred seventy-five individuals participated in three clinical trials enrolling breast (n=65), gastrointestinal (n=113), and lung (n=97) cancer patients. Internal consistency was evaluated using Cronbach's alpha coefficients calculated for six PCM subscales (general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation) and a Quality-of-Life Index. Construct validity was evaluated through Pearson's correlation between PCM subscales and subscales of the Functional Assessment of Cancer Therapy--General (FACT-G), the M.D. Anderson Symptom Inventory (MDASI), and the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F). The participants had the following characteristics: mean age was 58 years (standard deviation: 11), 52% were females, 79% were whites, 17% were blacks, 62% had no college degree, and 78% had metastatic or recurrent disease.

RESULTS

Raw and normalized scores for PCM 2.0 subscales were internally consistent across study cohorts. PCM 2.0 subscales correlated significantly (P<0.05) with the corresponding subscales on FACT-G, MDASI, and FACIT-F, with the exception of FACT-G social well-being, particularly for the lung cancer population. These correlations demonstrated construct validity. PCM 2.0 results followed expected patterns by cancer etiology. Prior reports demonstrate patient satisfaction with PCM 2.0.

CONCLUSION

Within three unique academic oncology populations, PCM 2.0 is a valid ePRO instrument for assessing symptoms with seven patient-centered subscale or index domains.

摘要

背景

患者护理监测器(PCM)是一种通过电子患者报告结果(ePRO)数据采集系统进行的系统回顾调查,该系统使用无线平板电脑。尽管 PCM 1.0 已得到验证,但更新后的 PCM 2.0 尚未在学术环境中进行验证或测试。

目的

在三种癌症人群中验证和测试 PCM 2.0。

方法

275 名个体参加了三项临床试验,招募了乳腺癌(n=65)、胃肠道癌(n=113)和肺癌(n=97)患者。使用 Cronbach's alpha 系数评估六个 PCM 分量表(一般身体症状、治疗副作用、困扰、绝望、功能受损和活动受限)和生活质量指数的内部一致性。通过 PCM 分量表与癌症治疗功能评估-一般(FACT-G)、安德森症状指数(MDASI)和慢性疾病治疗功能评估-疲劳(FACIT-F)的分量表之间的 Pearson 相关关系评估结构效度。参与者具有以下特征:平均年龄为 58 岁(标准差:11),52%为女性,79%为白人,17%为黑人,62%没有大学学历,78%患有转移性或复发性疾病。

结果

PCM 2.0 分量表的原始和归一化分数在研究队列中具有一致性。PCM 2.0 分量表与 FACT-G、MDASI 和 FACIT-F 的相应分量表显著相关(P<0.05),但 FACT-G 的社会福祉除外,特别是对于肺癌人群。这些相关性表明了结构效度。PCM 2.0 的结果符合癌症病因的预期模式。先前的报告表明患者对 PCM 2.0 满意。

结论

在三个独特的学术肿瘤学人群中,PCM 2.0 是一种有效的 ePRO 工具,可评估七个以患者为中心的分量表或指数领域的症状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验